keyword
MENU ▼
Read by QxMD icon Read
search

Cancer related anemia

keyword
https://www.readbyqxmd.com/read/28707393/malaria-epstein-barr-virus-infection-and-the-pathogenesis-of-burkitt-s-lymphoma
#1
Anthony R Mawson, Suvankar Majumdar
A geographical and causal connection has long been recognized between malaria, Epstein-Barr virus (EBV) infection and Burkitt's lymphoma (BL), but the underlying mechanisms remain obscure. Potential clues are that the malaria parasite Plasmodium falciparum selectively absorbs vitamin A from the host and depends on it for its biological activities; secondly, alterations in vitamin A (retinoid) metabolism have been implicated in many forms of cancer, including BL. The first author has proposed that the merozoite-stage malaria parasite, emerging from the liver, uses its absorbed vitamin A as a cell membrane destabilizer to invade the red blood cells, causing anemia and other signs and symptoms of the disease as manifestations of an endogenous form of hypervitaminosis A (Mawson AR...
July 13, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28707073/protective-effects-of-spatholobi-caulis-extract-on-neuronal-damage-and-focal-ischemic-stroke-reperfusion-injury
#2
Hee Ra Park, Heeeun Lee, Jung-Jin Lee, Nam-Hui Yim, Min-Jung Gu, Jin Yeul Ma
Neuronal apoptotic cell death plays an important role in many neurological disorders, including Alzheimer's disease, Parkinson's disease, and ischemic stroke. Spatholobi Caulis (SC) has been widely used in traditional herbal medicine for the treatment of cancer, inflammation, viral infection, and anemia. However, the protective effects of SC extract (SCE) against apoptotic cell death in the brain have not been reported. We investigated the protective effects of SCE against neuronal injury etoposide-induced neurotoxicity and in rats subjected to focal transient ischemic stroke middle cerebral artery occlusion (MCAO) for 45 min, followed by 7 days of reperfusion...
July 13, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28705540/three-year-safety-of-radium-223-dichloride-in-patients-with-castration-resistant-prostate-cancer-and-symptomatic-bone-metastases-from-phase-3-randomized-alpharadin-in-symptomatic-prostate-cancer-trial
#3
Christopher C Parker, Robert E Coleman, Oliver Sartor, Nicholas J Vogelzang, David Bottomley, Daniel Heinrich, Svein I Helle, Joe M O'Sullivan, Sophie D Fosså, Aleš Chodacki, Paweł Wiechno, John Logue, Mihalj Seke, Anders Widmark, Dag Clement Johannessen, Peter Hoskin, Nicholas D James, Arne Solberg, Isabel Syndikus, Jan Kliment, Steffen Wedel, Sibylle Boehmer, Marcos Dall'Oglio, Lars Franzén, Øyvind S Bruland, Oana Petrenciuc, Karin Staudacher, Rui Li, Sten Nilsson
BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment. OBJECTIVE: To report updated ALSYMPCA safety, including long-term safety up to 3 yr after the first injection. DESIGN, SETTING, AND PARTICIPANTS: Safety analyses from phase 3 randomized ALSYMPCA trial included patients receiving ≥1 study-drug injection (600 radium-223 and 301 placebo)...
July 10, 2017: European Urology
https://www.readbyqxmd.com/read/28687971/the-spectrum-of-genetic-variants-in-hereditary-pancreatic-cancer-includes-fanconi-anemia-genes
#4
Thomas P Slavin, Susan L Neuhausen, Bita Nehoray, Mariana Niell-Swiller, Ilana Solomon, Christina Rybak, Kathleen Blazer, Aaron Adamson, Kai Yang, Sharon Sand, Nancy Guerrero-Llamas, Danielle Castillo, Josef Herzog, Xiwei Wu, Shu Tao, Shivali Raja, Vincent Chung, Gagandeep Singh, Sue Nadesan, Sandra Brown, Marcia Cruz-Correa, Gloria M Petersen, Jeffrey Weitzel
Approximately 5-10% of all pancreatic cancer patients carry a predisposing mutation in a known susceptibility gene. Since >90% of patients present with late stage disease, it is crucial to identify high risk individuals who may be amenable to early detection or other prevention. To explore the spectrum of hereditary pancreatic cancer susceptibility, we evaluated germline DNA from pancreatic cancer participants (n = 53) from a large hereditary cancer registry. For those without a known predisposition mutation gene (n = 49), germline next generation sequencing was completed using targeted capture for 706 candidate genes...
July 8, 2017: Familial Cancer
https://www.readbyqxmd.com/read/28687786/involvement-of-fancd2-in-energy-metabolism-via-atp5%C3%AE
#5
Panneerselvam Jayabal, Chi Ma, Manoj Nepal, Yihang Shen, Raymond Che, James Turkson, Peiwen Fei
Growing evidence supports a general hypothesis that aging and cancer are diseases related to energy metabolism. However, the involvement of Fanconi Anemia (FA) signaling, a unique genetic model system for studying human aging or cancer, in energy metabolism remains elusive. Here, we report that FA complementation group D2 protein (FANCD2) functionally impacts mitochondrial ATP production through its interaction with ATP5α, whereas this relationship was not observed in the mutant FANCD2 (K561R)-carrying cells...
July 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28678401/assessing-the-spectrum-of-germline-variation-in-fanconi-anemia-genes-among-patients-with-head-and-neck-carcinoma-before-age-50
#6
Settara C Chandrasekharappa, Steven B Chinn, Frank X Donovan, Naweed I Chowdhury, Aparna Kamat, Adebowale A Adeyemo, James W Thomas, Meghana Vemulapalli, Caroline S Hussey, Holly H Reid, James C Mullikin, Qingyi Wei, Erich M Sturgis
BACKGROUND: Patients with Fanconi anemia (FA) have an increased risk for head and neck squamous cell carcinoma (HNSCC). The authors sought to determine the prevalence of undiagnosed FA and FA carriers among patients with HNSCC as well as an age cutoff for FA genetic screening. METHODS: Germline DNA samples from 417 patients with HNSCC aged <50 years were screened for sequence variants by targeted next-generation sequencing of the entire length of 16 FA genes...
July 5, 2017: Cancer
https://www.readbyqxmd.com/read/28669167/the-prognostic-value-of-pre-treatment-leukocytosis-in-patients-with-previously-treated-stage-iiib-iv-non-small-cell-lung-cancer-treated-with-the-igf-1r-pathway-modulator-axl1717-or-docetaxel-a-retrospective-analysis-of-a-phase-ii-trial
#7
Georg Holgersson, Michael Bergqvist, Jonas Nilsson, Marcus Thureson, Johan Harmenberg, Stefan Bergstrom
Background: The aim of the present study was to investigate any prognostic value of pre-treatment anemia, leukocytosis and thrombocytosis in patients with advanced pretreated NSCLC. Methods: A randomized, multicenter phase II study comparing the IGF-1R modulator AXL with standard docetaxel in the treatment of previously treated stage IIIB or IV NSCLC patients was conducted in 2011-2013. Clinical and laboratory data were collected, including serum values for hemoglobin (Hgb), white blood cells (WBC) and platelets (Plt) at baseline...
June 25, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28655807/germ-line-brca2-mutations-detected-in-pediatric-sequencing-studies-impact-parents-evaluation-and-care
#8
Michael F Walsh, Jennifer Kennedy, Megan Harlan, Alex Kentsis, Neerav Shukla, Stephen Roberts, Andrew L Kung, Mark Robson, Brian H Kushner, Paul Meyers, Kenneth Offit
There has been no indication to test for BRCA1/2 in children (with the rare exception of Fanconi Anemia) as screening begins in adult years and the potential to induce anxiety related to adult onset cancers. However in the setting of pediatric cancer, with increasing utility and frequency of companion tumor-normal sequencing without regard for phenotype and with BRCA1/2 included in tumor profiling panels, germline mutations in BRCA1/2 and other DNA damage repair genes have been found. When mutations in these genes are revealed, there are implications for immediate family members...
June 27, 2017: Cold Spring Harbor Molecular Case Studies
https://www.readbyqxmd.com/read/28652651/molecular-mimicry-in-helicobacter-pylori-infections
#9
REVIEW
Magdalena Chmiela, Weronika Gonciarz
Gram-negative bacteria Helicobacter pylori (H. pylori) colonize gastric mucosa in humans and increase the risk of serious diseases such as gastric and duodenal ulcers, stomach cancers and mucosa associated lymphoid tissue lymphoma. The role of H. pylori infection in the pathogenesis of several extragastric diseases has been suggested including immune thrombocytopenic purpura, iron deficiency anemia, vitamin D deficiency, cardiovascular diseases, diabetes mellitus and dermatological disorders. Also neurological diseases and even lung cancer have attracted researchers concern...
June 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28629521/erythropoietin-promotes-glioblastoma-via-mir-451-suppression
#10
Begum Alural, Zeynep O Ayyildiz, Kemal U Tufekci, Sermin Genc, Kursad Genc
Erythropoietin (EPO) is an erythropoiesis stimulating growth factor and hormone. EPO has been widely used in the treatment of chronic renal failure, cancer, and chemotherapy-related anemia for three decades. However, many clinical trials showed that EPO treatment may be associated with tumorigenesis and cancer progression. EPO is able to cross blood-brain barriers, and this may lead to an increased possibility of central nervous system tumors such as glioblastoma. Indeed, EPO promotes glioblastoma growth and invasion in animal studies...
2017: Vitamins and Hormones
https://www.readbyqxmd.com/read/28626256/postoperative-chemoradiation-therapy-using-high-dose-cisplatin-and-fluorouracil-for-high-and-intermediate-risk-uterine-cervical-cancer
#11
Rise Miyauchi, Yoshiyuki Itoh, Mariko Kawamura, Akihiro Hirakawa, Kiyosumi Shibata, Hiroaki Kajiyama, Rie Nakahara, Seiji Kubota, Junji Ito, Tohru Okada, Fumitaka Kikkawa, Shinji Naganawa
The purpose of this retrospective study was to analyze data in patients with stage IB-IIB uterine cervical cancer who were treated with concurrent chemoradiotherapy (CCRT) with high dose cisplatin and fluorouracil as postoperative adjuvant therapy. Between February 2003 and November 2011, 76 patients with FIGO stage IB-IIB cervical cancer were analyzed. Seventy patients were treated with postoperative CCRT and 6 patients were treated with radiation therapy alone. Data related to overall survival (OS), disease-free survival (DFS), toxicity, and failure pattern were analyzed...
February 2017: Nagoya Journal of Medical Science
https://www.readbyqxmd.com/read/28625825/red-blood-cell-transfusion-in-surgical-cancer-patients-targets-risks-mechanistic-understanding-and-further-therapeutic-opportunities
#12
REVIEW
Vassilis L Tzounakas, Jerard Seghatchian, Elissavet Grouzi, Styliani Kokoris, Marianna H Antonelou
Anemia is present in more than half of cancer patients and appears to be an independent prognostic factor of short- and long-term adverse outcomes. It increases in the advanced period of cancer and perioperatively, in patients with solid tumors who undergo surgery. As a result, allogeneic red blood cell (RBC) transfusion is an indispensable treatment in cancer. However, its safety remains controversial, based on several laboratory and clinical data reporting a linkage with increased risk for cancer recurrence, infection and cancer-related mortality...
May 26, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28611199/u-s-food-and-drug-administration-approval-summary-atezolizumab-for-metastatic-non-small-cell-lung-cancer
#13
Chana Weinstock, Sean Khozin, Daniel Suzman, Lijun Zhang, Shenghui Tang, Sakar Wahby, Kirsten B Goldberg, Geoffrey Kim, Richard Pazdur
On October 18 2016, the U.S. Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose disease progressed during or following platinum-containing chemotherapy. Approval was based on demonstration of clinically meaningful improvements in overall survival (OS) and an acceptable safety profile in two randomized clinical trials (OAK and POPLAR). Median OS in OAK, a phase III trial, was 13.8 months (95% confidence interval [CI] 11...
June 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28595616/phase-i-study-of-oral-ridaforolimus-in-combination-with-paclitaxel-and-carboplatin-in-patients-with-solid-tumor-cancers
#14
Hye Sook Chon, Sokbom Kang, Jae K Lee, Sachin M Apte, Mian M Shahzad, Irene Williams-Elson, Robert M Wenham
BACKGROUND: Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tolerated dose, and recommended phase II dose and schedule of oral ridaforolimus combined with paclitaxel and carboplatin in patients with solid tumor cancers. METHODS: Eligible patients with advanced solid tumor cancers received oral 10 to 30 mg ridaforolimus daily for 5 consecutive days per week combined with intravenous paclitaxel (175 mg/m(2)) and carboplatin (area under the curve [AUC] 5-6 mg/mL/min) in 3-week cycles...
June 8, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28588792/erythropoietin-for-cancer-associated-malignant-anemia-a-meta-analysis
#15
Feng Zhao, Yijuan Wang, Lin Liu, Meiling Bian
The present study aimed to evaluate the effectiveness of erythropoietin (EPO) for improving cancer-associated malignant anemia. A search was performed for randomized clinical trials, conducted according to the Cochrane manual, using electronic databases including PubMed, EMBASE, the Cochrane Library and ClinicalTrails.gov up to 15 August 2015. A total of 6 eligible studies from 5 articles enrolling a total of 453 patients were entered into the current meta-analysis. Upon EPO treatment, there were significant differences in the change in hemoglobin (HB) levels compared with the placebo at short-term follow-up [mean difference (MD)=0...
June 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28579318/the-zebrafish-kidney-mutant-zeppelin-reveals-that-brca2-fancd1-is-essential-for-pronephros-development
#16
Paul T Kroeger, Bridgette E Drummond, Rachel Miceli, Michael McKernan, Gary F Gerlach, Amanda N Marra, Annemarie Fox, Kristen K McCampbell, Ignaty Leshchiner, Adriana Rodriguez-Mari, Ruth BreMiller, Ryan Thummel, Alan J Davidson, John Postlethwait, Wolfram Goessling, Rebecca A Wingert
The zebrafish kidney is conserved with other vertebrates, making it an excellent genetic model to study renal development. The kidney collects metabolic waste using a blood filter with specialized epithelial cells known as podocytes. Podocyte formation is poorly understood but relevant to many kidney diseases, as podocyte injury leads to progressive scarring and organ failure. zeppelin (zep) was isolated in a forward screen for kidney mutants and identified as a homozygous recessive lethal allele that causes reduced podocyte numbers, deficient filtration, and fluid imbalance...
August 1, 2017: Developmental Biology
https://www.readbyqxmd.com/read/28573179/small-bowel-malignancy-in-patients-undergoing-capsule-endoscopy-at-a-tertiary-care-academic-center-case-series-and-review-of-the-literature
#17
Connor A Johnston, Diana E Yung, Alka Joshi, John N Plevris, Anastasios Koulaouzidis
BACKGROUND AND STUDY AIMS : Small bowel cancer is rare, accounting for < 5 % of all gastrointestinal neoplasms. Capsule endoscopy has become the procedure of choice for non-invasive diagnosis of small bowel diseases. Data on capsule endoscopy diagnosis of small bowel cancer are limited. The objective of the study was to determine the frequency, indications and diagnostic work-up of patients with small bowel malignancy found by capsule endoscopy at a Scottish tertiary center. PATIENTS AND METHODS : In this retrospective study, records all patients who underwent small bowel capsule endoscopy at our center over a 10-year period were reviewed for possible malignancy...
June 2017: Endoscopy International Open
https://www.readbyqxmd.com/read/28545381/prevalence-and-clinical-significance-of-visible-oral-lesions-in-patients-with-fanconi-anemia-at-risk-for-head-and-neck-cancer
#18
Eunike Velleuer, Ralf Dietrich, Amy Frohnmayer, Natalia Pomjanski, Laura E Hays, Stefan Biesterfeld
Fanconi anemia is a genetic bone marrow failure syndrome, variably associated with congenital anomalies and a sharply increased risk for epithelial malignancies. During the past 20 years, hematopoietic stem cell transplantation (HSCT) has dramatically improved survival. However, compared to the general population, FA patients are at greatly increased risk, and at a much younger age, for squamous cell carcinomas (SCC) of the oral cavity, esophagus and the anogenital region. The relative risk and age of onset appears to negatively correlate with HSCT in FA patients...
May 24, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28538387/prognostic-significance-of-urothelial-carcinoma-with-divergent-differentiation-in-upper-urinary-tract-after-radical-nephroureterectomy-without-metastatic-diseases-a-retrospective-cohort-study
#19
Chuan Qin, En-Li Liang, Zhi-Yong Du, Xiao-Yu Qiu, Gang Tang, Fei-Ran Chen, Bo Zhang, Da-Wei Tian, Hai-Long Hu, Chang-Li Wu
To evaluate the impact of urothelial carcinoma with divergent differentiation (UCDD) on the prognosis of patients for primary upper urinary tract urothelial carcinoma (UTUC) with pN0/x status treated with radical nephroureterectomy (RNU) and to evaluate the prognostic value of UCDD in different tumor locations (renal pelvis and ureter).Data from a total of 346 patients with UTUC who received RNU between January 2012 and March 2016 in the institution were retrospectively analyzed. Clinicopathological features and prognostic factors age, sex, complaint, height, weight, blood pressure, tumor grade, stage, smoking status, history of adjuvant chemotherapy, tumor location, history of bladder cancer, tumor necrosis, degree of hydronephrosis, tumor size, tumor focality, and preoperative anemia were compared between patients with pure UTUC and patients with UCDD...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28528916/indications-for-and-complications-of-transfusion-and-the-management-of-gynecologic-malignancies
#20
REVIEW
Paulina Cybulska, Cheryl Goss, William P Tew, Rekha Parameswaran, Yukio Sonoda
Anemia, which is highly prevalent in oncology patients, is one of the most established negative prognostic factors for several gynecologic malignancies. Multiple factors can cause or contribute to the development of anemia in patients with gynecologic cancers; these factors include blood loss (during surgery or directly from the tumor), renal impairment (caused by platinum-based chemotherapy), and marrow dysfunction (from metastases, chemotherapy, and/or radiation therapy). Several peri- and intra-operative strategies can be used to optimize patient management and minimize blood loss related to surgery...
May 18, 2017: Gynecologic Oncology
keyword
keyword
34939
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"